HOUSTON, Sept. 18 Today US Oncology, Inc., which supportsthe nation's foremost cancer treatment and research network, announced theappointment of Michael A. Sicuro as Executive Vice President and ChiefFinancial Officer. In this position Sicuro will lead and manage the financefunction and provide leadership on a wide range of financial, analytical,operational, and transactional issues, including accounting, financialreporting, treasury, tax, and financial planning and analysis.
Sicuro comes to US Oncology with more than 25 years of financial andoperating experience in a variety of industries including health care,technology, financial services and real estate. Most recently he was SeniorVice President, Chief Financial Officer at Asyst Technologies, Inc., a globalautomation and technology company. Sicuro holds a Bachelor of BusinessAdministration degree from Kent State University.
"Michael brings a wealth of knowledge and leadership to US Oncology and weare very pleased to have him as part of our team," said Bruce Broussard,President and Chief Executive Officer of US Oncology. "His expertise andexperience will continue to create operational efficiencies that will onlyimprove upon our strong performance and ensure our goal to enhance patientaccess to advanced cancer care through all phases of the delivery system."
"I am very excited to join the US Oncology team. The strength of thiscompany is a testament to its dedication and commitment to increase access tohigh quality cancer care to patients," said Sicuro. "I'm looking forward toworking to identify strategic opportunities that will support and strengthenthese goals."
Sicuro is based at the company's headquarters in Houston, Texas.
About US Oncology
US Oncology, headquartered in Houston, works closely with physicians,manufacturers and payers to identify and deliver innovative services thatenhance patient access to advanced cancer care. US Oncology supports one ofthe nation's foremost cancer treatment and research networks, accelerating theavailability and use of evidence-based medicine and shared best practices.
US Oncology's expertise in supporting every aspect of the cancer caredelivery system-from drug development to treatment and outcomes measurement,enables the company to help increase the efficiency and safety of cancer care.According to the company's last quarterly earnings report, US Oncology isaffiliated with 1,220 physicians operating in 480 locations, including 92radiation oncology facilities in 39 states. For more information, visit thecompany's Web site, http://www.usoncology.com.
SOURCE US Oncology, Inc.